MET and neoplasm: Besides HER2, the single injection of accessible lesions with CAR-T cells targeting c-Met, a cell-surface protein tyrosine kinase aberrantly expressed in BC, in a group of 6 patients with metastatic BC comprised by two ER+ tumors and 4 TN tumors, did not render measurable responses but elicited extensive tumor necrosis and loss of c-Met immunoreactivity at the injection site, and also translated into detectable levels of c-Met-CAR-T cell mRNA in peripheral blood (63).